Literature DB >> 31090087

Efficacy of Combined Intense Pulsed Light (IPL) With Fractional CO2 -Laser Ablation in the Treatment of Large Hypertrophic Scars: A Prospective, Randomized Control Trial.

Alexander A Daoud1, Chloe Gianatasio2, Ashley Rudnick2, Mary Michael3, JillS Waibel2.   

Abstract

BACKGROUND AND OBJECTIVES: Scar rehabilitation is a complex process that incorporates medical, surgical, and physical therapeutic measures to best restore function and visual normalcy. Lasers have emerged as essential tools in the management of scars, with devices available to address scar size, dyschromia, and contour irregularities. As different lasers treat these different features, multi-laser, same session therapeutic approaches may offer a more comprehensive approach to scar revision. In this study, we aim to demonstrate the effect of a combinatorial, same session treatment with intense pulsed light (IPL) and fractional ablative CO2 as compared to single laser treatment with fractional ablative CO2 laser alone or control in the treatment of mature hypertrophic scars.
MATERIALS AND METHODS: This institutional review board-approved, randomized controlled trial, enrolled 23 healthy adults with large (>100 cm2 ) hypertrophic scars who were randomized to one of three treatment arms: (i) IPL and CO2 ablative fractional laser (AFL), (ii) CO2 AFL alone, and (iii) control (no laser treatment). Subjects underwent a total of four treatment sessions at 6-8-week intervals with follow-up visits at 1, 3, and 6 months following the last treatment session. Primary endpoints included blinded scoring of before and after photographs via the Manchester Scar Scale (MSS). Secondary endpoints included the Patient-Observer Scar Assessment Scale (POSAS).
RESULTS: As compared to control and CO2 AFL laser alone, the combination of CO2 AFL and IPL demonstrated statistically significant improvement across a greater number of scar domains, as assessed by the MSS. 100% of subjects in both treatment groups showed a statistically significant decrease in the POSAS scale after the series of four treatment sessions. No adverse events were reported.
CONCLUSION: Treatment with combined IPL and CO2 AFL demonstrated higher average improvements across the majority of assessed scar domains, as compared to both control and CO2 laser alone. The difference was not statistically significant in overall MSS score as expected due to the role of CO2 as the main source of improvement. However, only the combination group had statistically significant improvement in both color and texture. These findings support the assertion that a multi-photo-thermolytic approach with combined IPL and CO2 AFL can have a positive impact on the treatment of hypertrophic scars by using multiple wavelengths to maximize laser-skin interactions in targeting the different chromophores expressed in scar tissue. Lasers Surg. Med.
© 2019 Wiley Periodicals, Inc. © 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  fractional laser; hypertrophic scar; intense pulsed light; laser; multi-laser; photothermolysis; scar revision

Year:  2019        PMID: 31090087     DOI: 10.1002/lsm.23092

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  3 in total

Review 1.  Laser therapy for treating hypertrophic and keloid scars.

Authors:  Rafael Leszczynski; Carolina Ap da Silva; Ana Carolina Pereira Nunes Pinto; Uliana Kuczynski; Edina Mk da Silva
Journal:  Cochrane Database Syst Rev       Date:  2022-09-26

2.  Angiogenic gene characterization and vessel permeability of dermal microvascular endothelial cells isolated from burn hypertrophic scar.

Authors:  Esteban A Molina; Brandon Hartmann; Mary A Oliver; Liam D Kirkpatrick; John W Keyloun; Lauren T Moffatt; Jeffrey W Shupp; Taryn E Travis; Bonnie C Carney
Journal:  Sci Rep       Date:  2022-07-18       Impact factor: 4.996

3.  Application effect of lattice laser in facial rejuvenation: A protocol for systematic review and meta-analysis.

Authors:  Dan Yan; Zechun Huang; Anli Zhang; Shuaihua Li; Yao Xiao
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.